TAILORED-CHIP Trial: Time-Dependent Antiplatelet Therapy in High-Risk PCI
Ahmed Bennis, Professor of Cardiology, shared a post on X:
”Temporal modulation (early escalation and late de-escalation) of antiplatelet therapy in patients undergoing complex high-risk PCI: rationale and design of the TAILORED-CHIP trial
TAILORED-CHIP trial is an investigator-initiated, multicentre, prospective randomised trial to evaluate the efficacy and safety of a time-dependent tailored antiplatelet therapy with an early (<6 months post-PCI) escalation (low-dose ticagrelor at 60 mg twice daily plus aspirin) and a late (>6 months post-PCI) de-escalation (clopidogrel monotherapy) in patients undergoing complex high-risk PCI as compared with standard DAPT (clopidogrel plus aspirin for 12 months).”
Read the full article here.
Title: Temporal modulation (early escalation and late de-escalation) of antiplatelet therapy in patients undergoing complex high-risk PCI: rationale and design of the TAILORED-CHIP trial
Authors: Hanbit Park, Do-Yoon Kang, Jung-Min Ahn, Sung-Cheol Yun, Kyoung-Ha Park, Se-Hun Kang, Jon Suh, Jang-Whan Bae, Sangwoo Park, Jang Hyun Cho, Jung-Won Suh, Bong-Ki Lee, Seung-Woon Rha, Hoyoun Won, Jae-Sik Jang, Moo Hyun Kim, Cheol Hyun Lee, Young Keun Ahn, Jun-Hyok Oh, Jae-Seok Bae, Chul Soo Park, Jaewoong Choi, Jin-Bae Lee, Se-Whan Lee, Sung-Ho Hur, Osung Kwon, Seung-Jung Park, Duk-Woo Park; on behalf of the TAILORED-CHIP trial investigators
Stay updated with Hemostasis Today.
-
Oct 14, 2025, 06:19Kay Sharma: I Feel Incredibly Proud and Honored to Share the Final Agenda for The ISTH Continuing Education Forum
-
Oct 14, 2025, 06:12Murray Adams: Professor Favaloro Presented Talks On The 100-Year History of von Willebrand Disease
-
Oct 14, 2025, 06:10Samuel Nweke on Significance of MPV in a CBC in Diagnosis
-
Oct 14, 2025, 06:09Francois Delvoye: 5 Days to Go Before the Belgian Stroke Council Scientific Workshop!
-
Oct 14, 2025, 06:08David Smadja: Honored to Take Part in This Special Event for World Thrombosis Day at UM6P University
-
Oct 14, 2025, 06:13Amaliris Guerra: Driving True Innovation in Preclinical Drug Development Related to Iron-Metabolism and Inflammation is One of My Passions!
-
Oct 13, 2025, 03:32Wolfgang Miesbach: This Study from Children's Hospital of Philadelphia Provides Crucial Insights Into Elevidys
-
Oct 13, 2025, 02:43Lukas Meyer and Colleagues on Reperfusion-dependent Treatment Effects of Thrombectomy in Large Ischemic Infarcts
-
Oct 12, 2025, 10:14Hatim Lokhandwala: Landmark HI-PRO Trial Redefines VTE Treatment Guidelines
-
Oct 12, 2025, 07:28Roberta Gualtierotti: rFVIIIFc and rFIXFc Ensured Effective Haemostasis and Favourable Safety in Major Orthopaedic Surgery
-
Oct 13, 2025, 02:46Flora Peyvandi: First Proposed Blood Test for Chronic Fatigue Syndrome - What Scientists Think
-
Oct 13, 2025, 02:44Silvio Maresca: Honored to be part of this international research project - ThrombUS+
-
Oct 10, 2025, 12:25Robert Lewis: T Cells Are Wonderful - But They Can't Do Everything
-
Oct 9, 2025, 13:03Peter Graves: When the Bleeding Does Not Stop
-
Oct 8, 2025, 12:44Bobur Kholikov: Thrombosis Diagnostics with YHLO
-
Oct 14, 2025, 06:11Souad Ahmed: It Was Such A Treat to Attend the 2025 AIMS Travelling Orator Session
-
Oct 14, 2025, 06:06Tara Miller: One of My Favorite Parts of My Job Is Partnering With Passionate Teams Like ISTH
-
Oct 14, 2025, 06:05Pierre Grès: Honored to Share With You My Recent Award for Best Oral Presentation And My Experiences at The Congress of SFTH
-
Oct 14, 2025, 01:16Louise Bannon: Thank You to My Dear Friend, Justin Romanello, Who Shared His Blood Clot Survivor Story With ISTH World Thrombosis Day Campaign
-
Oct 13, 2025, 03:44Jorge Monge: It Was An Honor to Take Part in the 3rd EBA Workshop on Rare Blood Provision